$4.14
2.59% today
Nasdaq, Apr 02, 09:19 pm CET
ISIN
US17248W3034
Symbol
CING
Sector
Industry

Cingulate Stock price

$4.25
+0.30 7.59% 1M
-0.67 13.62% 6M
-0.68 13.79% YTD
-8.83 67.51% 1Y
-439.75 99.04% 3Y
-1,063.75 99.60% 5Y
-1,063.75 99.60% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.05 1.16%
ISIN
US17248W3034
Symbol
CING
Sector
Industry

Key metrics

Market capitalization $13.65m
Enterprise Value $6.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.94
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-15.65m
Free Cash Flow (TTM) Free Cash Flow $-18.66m
Cash position $12.21m
EPS (TTM) EPS $-16.32
Short interest 2.62%
Show more

Is Cingulate a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Cingulate Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Cingulate forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Cingulate forecast:

Buy
100%

Financial data from Cingulate

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.65 0.65
12% 12%
-
-0.65 -0.65
12% 12%
-
- Selling and Administrative Expenses 4.89 4.89
20% 20%
-
- Research and Development Expense 9.45 9.45
39% 39%
-
-15 -15
32% 32%
-
- Depreciation and Amortization 0.65 0.65
12% 12%
-
EBIT (Operating Income) EBIT -16 -16
31% 31%
-
Net Profit -16 -16
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cingulate directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cingulate Stock News

Neutral
GlobeNewsWire
7 days ago
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission
Neutral
GlobeNewsWire
3 months ago
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5 million.
Neutral
GlobeNewsWire
5 months ago
On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301
More Cingulate News

Company Profile

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.

Head office United States
CEO Shane Schaffer
Employees 13
Founded 2013
Website www.cingulate.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today